search
Back to results

Brief CBT for Patients Undergoing TAVR

Primary Purpose

Depression, Anxiety

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Brief Bedside CBT
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Depression, Anxiety focused on measuring CBT, Brief Therapy, Bedside Intervention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults 18 years of age and older
  2. Voluntary participation
  3. Informed consent obtained
  4. Patients with severe aortic stenosis and high surgical risk who are undergoing TAVR

Exclusion Criteria:

  1. Current psychiatric instability (eg., suicidality, schizophrenia, bipolar disorder, active alcoholism or substance abuse)
  2. Severe cognitive impairment, i.e. dementia
  3. Life threatening co-morbidities
  4. Inability to provide consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Brief Bedside CBT

    Treatment As Usual

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from Baseline Score on Beck Depression Inventory II (BDI-II)
    21-item self-report questionnaire with good reliability and validity in assessing symptoms of depression. Total score range 0-63 with higher scores indicating a worse outcome. Total BDI-II scores are interpreted as follows, 0-13: minimal, 14-19: mild, 20-28: moderate, 29-63: severe. In this study, a score of 14 or greater, and 20 or greater, were used define subpopulations with significant symptoms of depression on the BDI-II.

    Secondary Outcome Measures

    Change from Baseline Score on State Trait Anxiety Inventory Form YI (STAI-YI)
    20-item self-report questionnaire with good internal consistency and construct validity in assessing symptoms of anxiety. Total score range 20-80 with higher scores indicating a worse outcome. The recommended cutoff score for clinically significant anxiety is 39 but a recent validity study of anxiety disorders in cardiac patients found ≥ 40 as an optimal cutoff score for screening the presence of an anxiety disorder. In this study, a score of 40 or greater, and 46 or greater, were used to define subpopulations with significant symptoms of anxiety on the STAI-Y1.
    Change from Baseline Score on Minnesota Living With Heart Failure Questionnaire (MLHFQ)
    21-item self-report questionnaire designed to measure the effects of heart failure and treatments for heart failure on and individual's quality of life. Total score range 0-105. The total score is considered a measurement of heart failure severity as indicated by its adverse effect on the respondent's life over the past month. In this study, the MLHFQ total score was used as a continuous measure of heart failure related quality of life. Higher scores indicate a worse outcome.
    Change from Baseline Score on 12-Item Short Form Health Survey (SF12v2)
    An abbreviated version of the 36-item Short Form Health Survey, which is a well-established measure assessing dimensions of mental and physical health. In this study, PCS and MCS summary scores were used as continuous measures of health-related quality of life. Scoring procedures involve computer-based scoring algorithms to calculate two summary scores, the physical component summary score (PCS) and mental component summary score (MCS), on a scale from 0 to 100 with a mean of 50 ± 10 that is normally distributed according to the adult U.S. population. Higher scores indicate a better outcome.

    Full Information

    First Posted
    January 3, 2019
    Last Updated
    January 8, 2019
    Sponsor
    Stanford University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03798548
    Brief Title
    Brief CBT for Patients Undergoing TAVR
    Official Title
    Brief Cognitive Behavioral Therapy for Patients Undergoing Transcatheter Aortic Valve Replacement: A Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    January 15, 2015 (Actual)
    Primary Completion Date
    March 31, 2017 (Actual)
    Study Completion Date
    May 15, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Stanford University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Adult patients scheduled to undergo TAVR were randomized to receive brief bedside cognitive behavioral therapy for depression/anxiety or treatment as usual.
    Detailed Description
    Depression and anxiety are common symptoms in patients undergoing cardiac surgery and associated with increased cardiac morbidity and decreased functional status. Cognitive behavioral therapy (CBT) has been shown to be an effective intervention to treat these symptoms after cardiac surgery, but has not yet been studied in patients undergoing less invasive cardiac procedures such as Transcatheter Aortic Valve Replacement (TAVR). This study will examine the effect of CBT on symptoms of anxiety and depression in patients undergoing TAVR. The CBT protocol was loosely structured on the Managing Depression and Anxiety using Education and Skills (MADES) protocol described in Dao and colleagues (2011). The current intervention was designed to address the needs of individuals who may develop anxiety or depression symptoms post-TAVR. The CBT intervention consisted of four 30 to 60-minute bedside treatment sessions with a trained clinician while the participant was hospitalized for TAVR. Main outcome measures were self-reported symptoms of depression and anxiety as measured by the Beck Depression Inventory-II and State Trait Anxiety Inventory Form Y1. Secondary outcomes included health related quality of life and hospital length of stay.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Depression, Anxiety
    Keywords
    CBT, Brief Therapy, Bedside Intervention

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Brief Bedside CBT versus Treatment As Usual
    Masking
    InvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    146 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Brief Bedside CBT
    Arm Type
    Experimental
    Arm Title
    Treatment As Usual
    Arm Type
    No Intervention
    Intervention Type
    Behavioral
    Intervention Name(s)
    Brief Bedside CBT
    Intervention Description
    4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
    Primary Outcome Measure Information:
    Title
    Change from Baseline Score on Beck Depression Inventory II (BDI-II)
    Description
    21-item self-report questionnaire with good reliability and validity in assessing symptoms of depression. Total score range 0-63 with higher scores indicating a worse outcome. Total BDI-II scores are interpreted as follows, 0-13: minimal, 14-19: mild, 20-28: moderate, 29-63: severe. In this study, a score of 14 or greater, and 20 or greater, were used define subpopulations with significant symptoms of depression on the BDI-II.
    Time Frame
    An average of 3 days post TAVR Procedure, 1-Month Follow Up
    Secondary Outcome Measure Information:
    Title
    Change from Baseline Score on State Trait Anxiety Inventory Form YI (STAI-YI)
    Description
    20-item self-report questionnaire with good internal consistency and construct validity in assessing symptoms of anxiety. Total score range 20-80 with higher scores indicating a worse outcome. The recommended cutoff score for clinically significant anxiety is 39 but a recent validity study of anxiety disorders in cardiac patients found ≥ 40 as an optimal cutoff score for screening the presence of an anxiety disorder. In this study, a score of 40 or greater, and 46 or greater, were used to define subpopulations with significant symptoms of anxiety on the STAI-Y1.
    Time Frame
    An average of 3 days post TAVR Procedure, 1-Month Follow Up
    Title
    Change from Baseline Score on Minnesota Living With Heart Failure Questionnaire (MLHFQ)
    Description
    21-item self-report questionnaire designed to measure the effects of heart failure and treatments for heart failure on and individual's quality of life. Total score range 0-105. The total score is considered a measurement of heart failure severity as indicated by its adverse effect on the respondent's life over the past month. In this study, the MLHFQ total score was used as a continuous measure of heart failure related quality of life. Higher scores indicate a worse outcome.
    Time Frame
    1-Month Follow Up
    Title
    Change from Baseline Score on 12-Item Short Form Health Survey (SF12v2)
    Description
    An abbreviated version of the 36-item Short Form Health Survey, which is a well-established measure assessing dimensions of mental and physical health. In this study, PCS and MCS summary scores were used as continuous measures of health-related quality of life. Scoring procedures involve computer-based scoring algorithms to calculate two summary scores, the physical component summary score (PCS) and mental component summary score (MCS), on a scale from 0 to 100 with a mean of 50 ± 10 that is normally distributed according to the adult U.S. population. Higher scores indicate a better outcome.
    Time Frame
    1-Month Follow Up

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults 18 years of age and older Voluntary participation Informed consent obtained Patients with severe aortic stenosis and high surgical risk who are undergoing TAVR Exclusion Criteria: Current psychiatric instability (eg., suicidality, schizophrenia, bipolar disorder, active alcoholism or substance abuse) Severe cognitive impairment, i.e. dementia Life threatening co-morbidities Inability to provide consent

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    21621227
    Citation
    Dao TK, Youssef NA, Armsworth M, Wear E, Papathopoulos KN, Gopaldas R. Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively in patients undergoing coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2011 Sep;142(3):e109-15. doi: 10.1016/j.jtcvs.2011.02.046. Epub 2011 May 28.
    Results Reference
    background
    Links:
    URL
    https://www.jtcvs.org/article/S0022-5223(11)00402-8/fulltext
    Description
    Link to Dao et al 2011

    Learn more about this trial

    Brief CBT for Patients Undergoing TAVR

    We'll reach out to this number within 24 hrs